Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker DNTH
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 17,724 | $90.56 | $1.6M Sale | Form 4 ↗ |
| Nov 11, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 3,044 | $90.03 | $274.1K Sale | Form 4 ↗ |
| Nov 10, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 2,561 | $90.14 | $230.8K Sale | Form 4 ↗ |
| Nov 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 2,064 | $91.59 | $189.0K Sale | Form 4 ↗ |
| Nov 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 58,396 | $90.90 | $5.3M Sale | Form 4 ↗ |
| Nov 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 37,517 | $90.12 | $3.4M Sale | Form 4 ↗ |
| Nov 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 1,736 | $88.84 | $154.2K Sale | Form 4 ↗ |
| Nov 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 700 | $86.70 | $60.7K Sale | Form 4 ↗ |
| Nov 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 300 | $85.16 | $25.5K Sale | Form 4 ↗ |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | DNTH Dianthus Therapeutics, Inc. | Sale | 700 | $104.39 | $73.1K Sale | Form 4 ↗ |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | DNTH Dianthus Therapeutics, Inc. | Sale | 1,100 | $103.20 | $113.5K Sale | Form 4 ↗ |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | DNTH Dianthus Therapeutics, Inc. | Sale | 3,501 | $102.39 | $358.5K Sale | Form 4 ↗ |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | DNTH Dianthus Therapeutics, Inc. | Sale | 6,771 | $101.37 | $686.4K Sale | Form 4 ↗ |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | DNTH Dianthus Therapeutics, Inc. | Sale | 7,928 | $100.43 | $796.2K Sale | Form 4 ↗ |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | DNTH Dianthus Therapeutics, Inc. | Sale | 13,309 | $106.74 | $1.4M Sale | Form 4 ↗ |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | DNTH Dianthus Therapeutics, Inc. | Sale | 7,215 | $106.25 | $766.6K Sale | Form 4 ↗ |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | DNTH Dianthus Therapeutics, Inc. | Sale | 2,600 | $105.19 | $273.5K Sale | Form 4 ↗ |
| Aug 19, 2026 | Simon Read Director | DNTH Dianthus Therapeutics, Inc. | Sale | 2,778 | $117.55 | $326.6K Sale | Form 4 ↗ |
| Aug 10, 2026 | Anne McGeorge Director | DNTH Dianthus Therapeutics, Inc. | Sale | 700 | $111.41 | $78.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | Anne McGeorge Director | DNTH Dianthus Therapeutics, Inc. | Sale | 1,000 | $110.64 | $110.6K Sale | Form 4 ↗ |
| Aug 10, 2026 | Anne McGeorge Director | DNTH Dianthus Therapeutics, Inc. | Sale | 1,800 | $109.30 | $196.7K Sale | Form 4 ↗ |
| Aug 10, 2026 | Anne McGeorge Director | DNTH Dianthus Therapeutics, Inc. | Sale | 2,800 | $108.38 | $303.5K Sale | Form 4 ↗ |
| Aug 10, 2026 | Anne McGeorge Director | DNTH Dianthus Therapeutics, Inc. | Sale | 1,450 | $107.58 | $156.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | Adam M. Veness SVP, General Counsel and Sec. | DNTH Dianthus Therapeutics, Inc. | Sale | 16,167 | $110.38 | $1.8M Sale | Form 4 ↗ |
| Aug 10, 2026 | Simon Read Director | DNTH Dianthus Therapeutics, Inc. | Sale | 397 | $111.77 | $44.4K Sale | Form 4 ↗ |
| Aug 10, 2026 | Simon Read Director | DNTH Dianthus Therapeutics, Inc. | Sale | 470 | $111.05 | $52.2K Sale | Form 4 ↗ |
| Aug 10, 2026 | Simon Read Director | DNTH Dianthus Therapeutics, Inc. | Sale | 272 | $109.96 | $29.9K Sale | Form 4 ↗ |
| Aug 10, 2026 | Simon Read Director | DNTH Dianthus Therapeutics, Inc. | Sale | 831 | $108.95 | $90.5K Sale | Form 4 ↗ |
| Aug 10, 2026 | Simon Read Director | DNTH Dianthus Therapeutics, Inc. | Sale | 737 | $108.17 | $79.7K Sale | Form 4 ↗ |
| Aug 10, 2026 | Simon Read Director | DNTH Dianthus Therapeutics, Inc. | Sale | 70 | $107.11 | $7,498 Sale | Form 4 ↗ |
| Aug 7, 2026 | Adam M. Veness SVP, General Counsel and Sec. | DNTH Dianthus Therapeutics, Inc. | Sale | 616 | $111.18 | $68.5K Sale | Form 4 ↗ |
| Aug 7, 2026 | Adam M. Veness SVP, General Counsel and Sec. | DNTH Dianthus Therapeutics, Inc. | Sale | 3,217 | $110.61 | $355.8K Sale | Form 4 ↗ |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT, Director | DNTH Dianthus Therapeutics, Inc. | Sale | 21,909 | $108.72 | $2.4M Sale | Form 4 ↗ |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT, Director | DNTH Dianthus Therapeutics, Inc. | Sale | 104,091 | $107.96 | $11.2M Sale | Form 4 ↗ |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT, Director | DNTH Dianthus Therapeutics, Inc. | Sale | 800 | $110.76 | $88.6K Sale | Form 4 ↗ |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT, Director | DNTH Dianthus Therapeutics, Inc. | Sale | 2,536 | $110.02 | $279.0K Sale | Form 4 ↗ |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT, Director | DNTH Dianthus Therapeutics, Inc. | Sale | 2,373 | $109.10 | $258.9K Sale | Form 4 ↗ |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT, Director | DNTH Dianthus Therapeutics, Inc. | Sale | 23,907 | $108.05 | $2.6M Sale | Form 4 ↗ |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT, Director | DNTH Dianthus Therapeutics, Inc. | Sale | 10,384 | $107.49 | $1.1M Sale | Form 4 ↗ |
| Jul 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 5,566 | $101.97 | $567.6K Sale | Form 4 ↗ |
| Jul 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 15,329 | $101.24 | $1.6M Sale | Form 4 ↗ |
| Jul 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 10,354 | $100.22 | $1.0M Sale | Form 4 ↗ |
| Jun 17, 2026 | Adam M. Veness SVP, General Counsel and Sec. | DNTH Dianthus Therapeutics, Inc. | Sale | 13,229 | $81.38 | $1.1M Sale | Form 4 ↗ |
| Jun 17, 2026 | Adam M. Veness SVP, General Counsel and Sec. | DNTH Dianthus Therapeutics, Inc. | Sale | 16,771 | $80.34 | $1.3M Sale | Form 4 ↗ |
| Jun 1, 2026 | Simrat Randhawa EVP, Head of R&D | DNTH Dianthus Therapeutics, Inc. | Sale | 4,159 | $91.37 | $380.0K Sale | Form 4 ↗ |
| Jun 1, 2026 | Simrat Randhawa EVP, Head of R&D | DNTH Dianthus Therapeutics, Inc. | Sale | 16,943 | $90.72 | $1.5M Sale | Form 4 ↗ |
| Jun 1, 2026 | Simrat Randhawa EVP, Head of R&D | DNTH Dianthus Therapeutics, Inc. | Sale | 5,428 | $89.72 | $487.0K Sale | Form 4 ↗ |
| May 8, 2026 | Paula Soteropoulos Director | DNTH Dianthus Therapeutics, Inc. | Sale | 599 | $85.47 | $51.2K Sale | Form 4 ↗ |
| Apr 9, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 8,224 | $89.84 | $738.8K Sale | Form 4 ↗ |
| Mar 31, 2026 | Ryan Savitz EVP, CFO & CBO | DNTH Dianthus Therapeutics, Inc. | Sale | 7,232 | $85.54 | $618.6K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:11 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances